If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

J. Scott Wolchko net worth and biography

J. Wolchko Biography and Net Worth

CEO of Fate Therapeutics

Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of Morgan Stanley’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., where he oversaw all corporate service-related operations, and previously led Corporate Development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.

What is J. Scott Wolchko's net worth?: The estimated net worth of J. Scott Wolchko is at least $2.08 million as of January 10th, 2023. Mr. Wolchko owns 385,639 shares of Fate Therapeutics stock worth more than $2,078,594 as of March 26th. This net worth approximation does not reflect any other investments that Mr. Wolchko may own. Learn More about J. Scott Wolchko's net worth.
How do I contact J. Scott Wolchko?: The corporate mailing address for Mr. Wolchko and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected] Learn More on J. Scott Wolchko's contact information.
Has J. Scott Wolchko been buying or selling shares of Fate Therapeutics?: During the last quarter, J. Scott Wolchko has sold $240,552.68 in shares of Fate Therapeutics stock. Most recently, J Scott Wolchko sold 45,907 shares of the business's stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $5.24, for a transaction totalling $240,552.68. Following the completion of the sale, the chief executive officer now directly owns 385,639 shares of the company's stock, valued at $2,020,748.36. Learn More on J. Scott Wolchko's trading history.
Who are Fate Therapeutics' active insiders?: Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.
Are insiders buying or selling shares of Fate Therapeutics?: In the last year, Fate Therapeutics insiders bought shares 2 times. They purchased a total of 124,679 shares worth more than $698,138.49. In the last year, insiders at the biopharmaceutical company sold shares 13 times. They sold a total of 192,987 shares worth more than $4,360,813.19. The most recent insider tranaction occured on January, 13th when Director John Mendlein bought 36,631 shares worth more than $198,906.33. Insiders at Fate Therapeutics own 17.3% of the company. Learn More about insider trades at Fate Therapeutics.
Information on this page was last updated on 1/13/2023.

J. Scott Wolchko Insider Trading History at Fate Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/10/2023	Sell	45,907	$5.24	$240,552.68	385,639
7/21/2022	Sell	30,000	$32.88	$986,400.00	431,546
4/21/2022	Sell	30,000	$35.00	$1,050,000.00	431,546
1/20/2022	Sell	30,000	$40.21	$1,206,300.00
1/10/2022	Sell	34,156	$46.86	$1,600,550.16
11/18/2021	Sell	20,000	$54.27	$1,085,400.00
10/21/2021	Sell	30,000	$60.22	$1,806,600.00
8/19/2021	Sell	20,000	$88.01	$1,760,200.00
7/22/2021	Sell	30,000	$86.05	$2,581,500.00
4/23/2021	Sell	30,000	$85.24	$2,557,200.00	423,793
1/21/2021	Sell	30,000	$103.05	$3,091,500.00	393,793
1/11/2021	Sell	69,407	$116.33	$8,074,116.31	393,065
1/8/2021	Sell	60,820	$117.10	$7,122,022.00	393,065
11/13/2020	Sell	60,000	$51.87	$3,112,200.00
1/30/2020	Sell	25,000	$25.45	$636,250.00	444,969
12/20/2019	Sell	25,000	$20.17	$504,250.00	378,969
10/15/2019	Sell	21,017	$14.44	$303,485.48
5/16/2019	Sell	14,335	$19.37	$277,668.95	389,216
4/17/2019	Sell	8,541	$16.17	$138,107.97	375,973
3/21/2019	Sell	20,000	$17.61	$352,200.00
4/1/2014	Sell	20,000	$9.64	$192,800.00

J. Scott Wolchko Buying and Selling Activity at Fate Therapeutics

Fate Therapeutics Company Overview

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Today's Range

Now: $5.39

$5.05

$5.43

50 Day Range

MA: $5.89

$4.88

$6.87

2 Week Range

Now: $5.39

$4.02

$43.12

Volume

1,708,987 shs

Average Volume

3,514,024 shs

Market Capitalization

$529.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

The Safest Option in Trades!

From Tradewins | Ad

Click here now!